SCHEMBL581124

SCHEMBL581124

O=C(O)c1cccc2c1C(=O)c1ccccc1-2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 1.00
MAPT P10636 3/20 1.00
LMNA P02545 3/20 1.00
L3MBTL1 Q9Y468 1/20 0.85
POLB P06746 3/20 0.68
NPC1 O15118 1/20 0.60
TTR P02766 1/20 0.57
GLA P06280 1/20 0.57
HTT P42858 1/20 0.57
MEN1 O00255 1/20 0.54
THRB P10828 1/20 0.54
MAPK1 P28482 1/20 0.54
RECQL P46063 1/20 0.54
KMT2A Q03164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL461660 0.92 ALDH1A1 (1.00) ALDH1A1MAPTLMNAL3MBTL1POLB
Anthraquinone SCHEMBL8941397 0.92 ALDH1A1 (1.00) ALDH1A1MAPTLMNAL3MBTL1POLB
Hydrochloric Acid SCHEMBL8675457 0.90 ALDH1A1 (0.96) ALDH1A1MAPTLMNAL3MBTL1POLB
SCHEMBL5866519 0.90 ALDH1A1 (0.81) ALDH1A1MAPTLMNAL3MBTL1POLB
SCHEMBL69132 0.90 ALDH1A1 (0.88) ALDH1A1MAPTLMNAL3MBTL1POLB
SCHEMBL4321962 0.87 ALDH1A1 (0.76) ALDH1A1MAPTLMNAL3MBTL1POLB
SCHEMBL3616574 0.85 ALDH1A1 (0.74) ALDH1A1MAPTLMNAL3MBTL1POLB
SCHEMBL31278212 0.85 ALDH1A1 (0.74) ALDH1A1MAPTLMNAL3MBTL1POLB
SCHEMBL29568790 0.85 MAPT (0.74) ALDH1A1MAPTLMNAL3MBTL1POLB
SCHEMBL71118 0.85 MAPT (0.74) ALDH1A1MAPTLMNAL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 729 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-115093794-B Polysilicon polishing composition and application thereof 万华化学集团电子材料有限公司 2023-10-13 CN claimed
CN-115093794-A Polysilicon polishing composition and application thereof 万华化学集团电子材料有限公司 2022-09-23 CN claimed
CN-111326656-B Solid additive for organic polymer solar cell 北京师范大学 2022-06-07 CN claimed
CN-111326656-A Solid additive for organic polymer solar cell 北京师范大学 2020-06-23 CN claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
EP-1989166-B1 VERSATILE OXIDATION BYPRODUCT PURGE PROCESS GRUPO PETROTEMEX SA DE CV (MX) 2017-09-06 EP claimed
EP-1429768-B1 NOVEL MEDICAMENTS FOR INHALATION BOEHRINGER INGELHEIM PHARMA (DE) 2016-11-16 EP claimed
WO-2004089416-A2 COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT NOVO NORDISK A/S (DK) 2004-10-21 WO claimed
WO-2004089470-A2 NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF NOVO NORDISK A/S (DK) 2004-10-21 WO claimed
WO-2004089415-A2 COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST NOVO NORDISK A/S (DK) 2004-10-21 WO claimed
WO-2004026843-A1 BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ARROW THERAPEUTICS LIMITED (GB) 2004-04-01 WO claimed
US-20030130300-A1 Respiratory system disorders; synergistic mixtures BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-10 US claimed
EP-0869947-B1 BARBITURIC ACID DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS ROCHE DIAGNOSTICS GMBH (DE) 2002-10-23 EP claimed
US-6368778-B1 FLUORENONE, FLUORENE, COUMARIN, NAPHTHALIC ACID IMIDE, PYRAZOLINE, OR ANTHRACENE IMAGE STABILIZER COMPOUNDS IN THE SILVER LAYER REDUCE IMAGE BROWNING; STABLE TO LIGHT AND HEAT OVER TIME PARTICULARLY UNDER LIGHT-BOX CONDITIONS EASTMAN KODAK COMPANY 2002-04-09 US claimed
EP-0147226-B1 VISIBLE LIGHT ABSORBING PEROXY ESTERS LOCTITE CORPORATION (US) 1989-11-23 EP claimed
US-4604295-A VISIBLE AND UV PHOTOINITIATORS FOR CURING ACRYLIC MONOMERS AND PREPOLYMERS LOCTITE CORPORATION (US) 1986-08-05 US claimed
EP-0147226-A2 Visible light absorbing peroxy esters LOCTITE CORPORATION (US) 1985-07-03 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS ALDH1A1 3087/4885MAPT 2153/4885LMNA 4734/4885
US-20030130300-A1 Respiratory system disorders; synergistic mixtures ADRB3, ADRB1, CHRM3 ALDH1A1 2866/4885MAPT 2558/4885LMNA 4366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.